Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Trovax · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Trovax | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Trovax | BIOLOGICAL | 1ml IM injection 2-8 weeks apart. |
| Placebo | BIOLOGICAL | Placebo |
| Standard of care therapy | BIOLOGICAL | subcutaneous low dose IL-2, interferon-α or sunitinib |
Inclusion Criteria: * Signed informed consent. The patient must be competent to give written informed consent and comply with the protocol requirements. * Locally advanced or metastatic, histologically proven clear cell renal carcinoma. * Primary tumour surgically removed (some residual advanced pr...
Trovax is an investigational monoclonal antibody being studied for the treatment of Clear Cell Renal Carcinoma, a type of kidney cancer. It is currently in Phase 3 clinical development and has not been approved by the FDA. The drug is being evaluated for its potential to improve survival outcomes in patients with this condition.
Trovax is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of Trovax in patients with Clear Cell Renal Carcinoma.
Trovax is currently in Phase 3 clinical development. This is the final stage of testing before a potential regulatory submission. The drug is being studied in a large, randomized, double-blind, placebo-controlled trial to assess its effectiveness in treating Clear Cell Renal Carcinoma.
Trovax is being evaluated in a Phase 3 clinical trial with the identifier NCT00397345, titled "TroVax Renal Immunotherapy Survival Trial." This completed trial enrolled 733 participants with Clear Cell Renal Carcinoma across multiple countries, including the United States, France, Germany, Israel, Poland, Romania, Russia, Spain, Ukraine, and the United Kingdom.
Yes, Trovax is also known as TroVax. The drug is referred to by both names in clinical research and development contexts. The Phase 3 trial for this drug is titled "TroVax Renal Immunotherapy Survival Trial," confirming that Trovax and TroVax refer to the same investigational therapy.